Literature DB >> 24810871

Metacognitive therapy versus cognitive behavioural therapy for depression: a randomized pilot study.

Jennifer Jordan1, Janet D Carter2, Virginia V W McIntosh3, Kumari Fernando4, Christopher M A Frampton4, Richard J Porter4, Roger T Mulder4, Cameron Lacey5, Peter R Joyce4.   

Abstract

OBJECTIVE: Metacognitive therapy (MCT) is one of the newer developments within cognitive therapy. This randomized controlled pilot study compared independently applied MCT with cognitive behavioural therapy (CBT) in outpatients with depression to explore the relative speed and efficacy of MCT, ahead of a planned randomized controlled trial.
METHOD: A total of 48 participants referred for outpatient therapy were randomized to up to 12 weeks of MCT or CBT. Key outcomes were reduction in depressive symptoms at week 4 and week 12, measured using the independent-clinician-rated Quick Inventory of Depressive Symptomatology16. Intention-to-treat and completer analyses as well as additional methods of reporting outcome of depression are presented.
RESULTS: Both therapies were effective in producing clinically significant change in depressive symptoms, with moderate-to-large effect sizes obtained. No differences were detected between therapies in overall outcome or early change on clinician-rated or self-reported measures. Post-hoc analyses suggest that MCT may have been adversely affected by greater comorbidity.
CONCLUSIONS: In this large pilot study conducted independently of MCT's developers, MCT was an effective treatment for outpatients with depression, with similar results overall to CBT. Insufficient power and imbalanced comorbidity limit conclusions regarding comparative efficacy so further studies of MCT and CBT are required. © The Royal Australian and New Zealand College of Psychiatrists 2014.

Entities:  

Keywords:  Cognitive behavioural therapy; depression; metacognitive; randomized pilot study

Mesh:

Year:  2014        PMID: 24810871     DOI: 10.1177/0004867414533015

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  9 in total

1.  Confidence at the limits of human nested cognition.

Authors:  Samuel Recht; Ljubica Jovanovic; Pascal Mamassian; Tarryn Balsdon
Journal:  Neurosci Conscious       Date:  2022-10-15

2.  Parental Factors Associated with Rumination Related Metacognitive Beliefs in Adolescence.

Authors:  Ka-Wai Chow; Barbara C Y Lo
Journal:  Front Psychol       Date:  2017-04-10

3.  Metacognitive Therapy for Depression in Adults: A Waiting List Randomized Controlled Trial with Six Months Follow-Up.

Authors:  Roger Hagen; Odin Hjemdal; Stian Solem; Leif Edward Ottesen Kennair; Hans M Nordahl; Peter Fisher; Adrian Wells
Journal:  Front Psychol       Date:  2017-01-24

4.  A Randomized Controlled Trial Comparing the Attention Training Technique and Mindful Self-Compassion for Students With Symptoms of Depression and Anxiety.

Authors:  Ragni B Haukaas; Ingrid B Gjerde; Grunde Varting; Håvard E Hallan; Stian Solem
Journal:  Front Psychol       Date:  2018-05-25

5.  PRO*MDD Study Protocol: Effectiveness of Outpatient Treatment Programs for Major Depressive Disorder: Metacognitive Therapy vs. Behavioral Activation a Single-Center Randomized Clinical Trial.

Authors:  Anja Schaich; Laura Heikaus; Nele Assmann; Sandra Köhne; Kamila Jauch-Chara; Michael Hüppe; Adrian Wells; Ulrich Schweiger; Jan Philipp Klein; Eva Fassbinder
Journal:  Front Psychiatry       Date:  2018-11-19       Impact factor: 4.157

6.  A Comparison of Metacognitive Therapy in Current Versus Persistent Depressive Disorder - A Pilot Outpatient Study.

Authors:  Lotta Winter; Julia Gottschalk; Janina Nielsen; Adrian Wells; Ulrich Schweiger; Kai G Kahl
Journal:  Front Psychol       Date:  2019-08-06

7.  The Efficacy of Metacognitive Therapy: A Systematic Review and Meta-Analysis.

Authors:  Nicoline Normann; Nexhmedin Morina
Journal:  Front Psychol       Date:  2018-11-14

8.  Activation therapy for the treatment of inpatients with depression - protocol for a randomised control trial compared to treatment as usual.

Authors:  Ian R E Averill; Ben Beaglehole; Katie M Douglas; Jennifer Jordan; Marie T Crowe; Maree Inder; Cameron J Lacey; Christopher M Frampton; Christopher R Bowie; Richard J Porter
Journal:  BMC Psychiatry       Date:  2019-02-01       Impact factor: 3.630

9.  Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial.

Authors:  Gholam Reza Kheirabadi; Zahra Yousefian; Fatemeh Zargar; Mahboobe Bahrami; Mohammad R Maracy
Journal:  J Educ Health Promot       Date:  2020-01-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.